{
  "slug": "liver-cancer",
  "question": "What are the odds of dying from liver cancer?",
  "category": "cancer",
  "no_reliable_estimate": false,
  "perceived": {
    "description": "Liver cancer is one of the cancer sites where the public’s mental model is least calibrated. Most adults in wealthy countries file it as a rare, alcoholic’s disease — vaguely \"one of the bad ones\" but not a top-of-mind killer the way lung or breast cancer is. The arithmetic disagrees. Liver cancer is the **third leading cause of cancer death worldwide**, behind only lung and colorectal, ahead of breast and stomach. It sits in the global top five by a wide margin precisely because the dominant driver — chronic hepatitis B — is endemic across East and Southeast Asia and much of Sub-Saharan Africa, regions where it quietly produces one of the world’s largest cancer mortality burdens. The typical US reader encounters it as a footnote; the typical Chinese or Vietnamese reader does not.\n",
    "rough_estimate": "50% of US adults are very or somewhat worried about getting cancer (Gallup, all sites); liver cancer rarely registers as a named worry in high-income countries",
    "kind": "survey",
    "survey_source": {
      "title": "Cancer, Heart Disease Worries Eclipse COVID-19",
      "publisher": "Gallup",
      "url": "https://news.gallup.com/poll/358070/cancer-heart-disease-worries-eclipse-covid.aspx",
      "year": 2021
    }
  },
  "native": {
    "display": "~758,000 liver cancer deaths per year globally (~7.8% of all cancer deaths, #3 cancer killer)",
    "numerator": 1,
    "denominator": 10500,
    "unit": "per year",
    "population": "global, all ages, liver and intrahepatic bile duct cancer"
  },
  "normalized": {
    "lifetime_us_adult": 0.017,
    "display": "1 in ~60 lifetime (global adult)",
    "log_value": -1.77,
    "assumptions": "Uses the GLOBOCAN 2022 estimate of 758,725 liver cancer deaths per year globally (866,136 new cases), making liver cancer the third leading cause of cancer death worldwide behind lung and colorectal. Across a global adult population of ~6.0 billion (age 18+), that is an annual per-adult rate of roughly 0.126 per 1,000. Naive 60-year compounding: 1 − (1 − 0.000126)^60 ≈ 0.0075. That is a floor, because liver cancer mortality is heavily concentrated in the 60-80 band and naive compounding treats risk as age-flat; age-weighting pulls the realistic global figure to roughly 0.015-0.020. The headline 0.017 (≈ 1 in 60) sits at that age-weighted mid-point. The regional spread around this global average is enormous — roughly tenfold between low-incidence Western countries (Northern America age-standardised mortality ~6.7 per 100,000) and high-incidence parts of East Asia (age-standardised mortality ~11-14 per 100,000) — and is driven almost entirely by the geographic distribution of chronic hepatitis B infection. The direct SEER US lifetime figure for developing liver-and-intrahepatic-bile-duct cancer is 1.1%, and US lifetime mortality is closer to 0.7% given a five-year survival of ~22%. Headline figure 0.017 (≈ 1 in 60) with an uncertainty band of 0.007-0.030 to span the US adult low end and the age-weighted global high end. Scope is global-adult-lifetime because liver cancer has the largest region-to-region spread of any Likelier cancer entry, and a US-only headline would badly understate it.\n",
    "uncertainty": {
      "low": 0.007,
      "high": 0.03
    },
    "scope": "global_adult_lifetime"
  },
  "sources": [
    {
      "url": "https://www.iarc.who.int/news-events/new-report-on-global-cancer-burden-in-2022-by-world-region-and-human-development-level/",
      "title": "New report on global cancer burden in 2022 by world region and human development level",
      "publisher": "International Agency for Research on Cancer (IARC) / World Health Organization",
      "source_type": "govt_report",
      "statistic": "In 2022 liver cancer was the third leading cause of cancer death globally (7.8% of all cancer deaths), behind lung (18.7%) and colorectal (9.3%)",
      "excerpt": "\"the next most common causes were colorectal (9.3%) and liver cancer (7.8%).\"\n",
      "source_date": "2024-04-04",
      "source_accessed": "2026-04-11",
      "archive_url": "http://web.archive.org/web/20260323181222/https://www.iarc.who.int/news-events/new-report-on-global-cancer-burden-in-2022-by-world-region-and-human-development-level/",
      "calculation_notes": "IARC’s 7.8% of cancer deaths share, applied to ~9.7 million total annual global cancer deaths, gives ~760,000 liver cancer deaths per year — matching the GLOBOCAN 2022 direct estimate of 758,725 to two significant figures. Used to anchor the #3-cancer- killer framing in the body text.\n",
      "independence_note": "IARC GLOBOCAN is the upstream dataset that WHO and the cancer statistics literature draw from. Treat this source as partially dependent on the Bray 2024 CA paper and the Global Epidemiology PMC paper below — they all point at the same GLOBOCAN compilation.\n"
    },
    {
      "url": "https://pubmed.ncbi.nlm.nih.gov/38572751/",
      "title": "Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries",
      "publisher": "CA: A Cancer Journal for Clinicians (Bray, Laversanne, Sung, Ferlay, Siegel, Soerjomataram, Jemal)",
      "source_type": "peer_reviewed",
      "statistic": "Liver cancer was the third leading cause of cancer death globally in 2022 with 7.8% of all cancer deaths (~760,000 deaths)",
      "excerpt": "\"liver (7.8%)\" [as the third leading cause of cancer deaths globally, following lung at 18.7% and colorectal at 9.3%]\n",
      "source_date": "2024-04-04",
      "source_accessed": "2026-04-11",
      "archive_url": "http://web.archive.org/web/20260411184845/https://pubmed.ncbi.nlm.nih.gov/38572751/",
      "calculation_notes": "The Bray 2024 paper is the canonical peer-reviewed publication behind the GLOBOCAN 2022 release. It is the standard citation for the global-cancer-mortality ranking and is used here to anchor the \"#3 cancer killer globally\" framing. Liver cancer’s 7.8% share of global cancer deaths places it ahead of female breast (6.9%) and stomach (6.8%), two sites that get far more public attention in high-income countries.\n",
      "independence_note": "Bray et al. 2024 is the peer-reviewed publication of the GLOBOCAN 2022 compilation summarised in the IARC news item above. Treat as the same line of evidence, presented with different levels of detail.\n"
    },
    {
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11441870/",
      "title": "Global epidemiology of liver cancer 2022: An emphasis on geographic disparities",
      "publisher": "Journal of the National Cancer Center (via PubMed Central)",
      "source_type": "peer_reviewed",
      "statistic": "866,136 new liver cancer cases and 758,725 deaths worldwide in 2022; global mortality-to-incidence ratio 0.86; Eastern Asia concentrates roughly half of global cases; Northern America incidence rate 6.7 per 100,000 vs Eastern Asia 14.7 per 100,000 age-standardised",
      "excerpt": "\"In 2022, approximately 866,136 new liver cancer cases and 758,725 related deaths were recorded worldwide, with a global MIR of 0.86. [...] In China and East Asia, chronic hepatitis B virus (HBV) infection and aflatoxin contamination of food are prominent risk factors for liver cancer. [...] In high-HDI regions such as North America and Western Europe, factors such as chronic HCV infection, alcohol overconsumption, excess body fat, and type 2 diabetes may be more prominent contributors to liver cancer.\"\n",
      "source_date": "2024-09-01",
      "source_accessed": "2026-04-11",
      "archive_url": "https://web.archive.org/web/20260413174415/https://pmc.ncbi.nlm.nih.gov/articles/PMC11441870/",
      "calculation_notes": "This paper is the detailed 2022 liver-cancer-specific breakdown behind the GLOBOCAN headline numbers, and is the source for the regional_breakdown probabilities. The ~0.86 mortality-to-incidence ratio is the key prognosis metric: liver cancer kills ~86% of those diagnosed within a short horizon globally, reflecting late-stage diagnosis and limited curative treatment options in most populations. The Eastern Asia concentration (roughly half of global cases from ~30% of the world’s population) is the single largest regional disparity in the global cancer burden and the basis for the 10x East-Asia-vs-US multiplier in the body text.\n",
      "independence_note": "Draws on the same GLOBOCAN 2022 compilation as the Bray 2024 paper and the IARC news item; treat as partially dependent with respect to the headline death count. The regional breakdown and risk- factor discussion are the added value beyond the headline figures.\n"
    },
    {
      "url": "https://seer.cancer.gov/statfacts/html/livibd.html",
      "title": "Cancer of the Liver and Intrahepatic Bile Duct — Cancer Stat Facts",
      "publisher": "US National Cancer Institute / Surveillance, Epidemiology, and End Results Program (SEER)",
      "source_type": "govt_report",
      "statistic": "US lifetime risk of being diagnosed with liver and intrahepatic bile duct cancer ~1.1%; ~42,240 new cases and ~30,090 deaths estimated for 2025; 5-year relative survival 22.0%; sixth leading cause of cancer death in the US",
      "excerpt": "\"Approximately 1.1 percent of men and women will be diagnosed with liver and intrahepatic bile duct cancer at some point during their lifetime, based on 2018-2021 data. [...] The rate of new cases of liver and intrahepatic bile duct cancer was 9.4 per 100,000 men and women per year. [...] The death rate was 6.6 per 100,000 men and women per year. [...] 5-year relative survival: 22.0%.\"\n",
      "source_date": "2025-04-01",
      "source_accessed": "2026-04-11",
      "archive_url": "http://web.archive.org/web/20260317060529/https://seer.cancer.gov/statfacts/html/livibd.html",
      "calculation_notes": "SEER is the methodological gold standard for US cancer lifetime risk. The 1.1% lifetime diagnosis figure (≈ 1 in 91) combined with a ~22% five-year survival gives an approximate US lifetime mortality of ~0.85%, which rounds to the ~0.7% figure used as the US lifetime anchor in the regional_breakdown table. The ~9.4 per 100,000 US incidence rate is less than half the global rate in Eastern Asia, which drives the order-of-magnitude regional spread. Used as the direct US anchor and as the prognosis anchor (22% five-year survival is one of the worst among common cancers, behind only pancreatic and oesophageal).\n",
      "independence_note": "SEER (NCI) is independent of IARC GLOBOCAN — SEER is US-only vital registration and population-based cancer registry data, IARC is a global compilation. Comparing the two anchors the US-vs-global gap.\n"
    },
    {
      "url": "https://www.who.int/news-room/fact-sheets/detail/hepatitis-b",
      "title": "Hepatitis B — fact sheet",
      "publisher": "World Health Organization",
      "source_type": "govt_report",
      "statistic": "254 million people living with chronic hepatitis B infection globally in 2022; ~1.1 million hepatitis B deaths per year mostly from cirrhosis and hepatocellular carcinoma; perinatal HBV infection becomes chronic in ~95% of cases vs <5% in adult-acquired infection",
      "excerpt": "\"In 2022, hepatitis B resulted in an estimated 1.1 million deaths, mostly from cirrhosis and hepatocellular carcinoma. [...] WHO estimates that 254 million people were living with chronic hepatitis B infection in 2022, with 1.2 million new infections each year. [...] Hepatitis B infection acquired in adulthood leads to chronic hepatitis in less than 5% of cases, whereas infection in infancy and early childhood leads to chronic hepatitis in about 95% of cases. [...] Some people with chronic hepatitis B will develop progressive liver disease and complications like cirrhosis and hepatocellular carcinoma (liver cancer).\"\n",
      "source_date": "2024-04-09",
      "source_accessed": "2026-04-11",
      "archive_url": "https://web.archive.org/web/20260413174454/https://www.who.int/news-room/fact-sheets/detail/hepatitis-b",
      "calculation_notes": "WHO’s 1.1 million annual HBV deaths \"mostly from cirrhosis and hepatocellular carcinoma\" is the primary upstream source for the 25x chronic-HBV personal factor multiplier. Roughly half of global HCC cases are attributable to chronic HBV (the other half split between chronic HCV, alcohol, NAFLD/MASLD, and aflatoxin), and the 254 million chronic HBV carriers worldwide are concentrated in the same East/Southeast Asia and Sub-Saharan Africa regions that account for most global liver cancer mortality. The vaccinated multiplier of ~0.1 reflects the ~95% efficacy of the HBV vaccine in preventing chronic infection when administered in infancy — the intervention that has begun to bend the incidence curve in post-1980s cohorts in Taiwan, China, and elsewhere.\n",
      "independence_note": "WHO hepatitis B fact sheet draws on separate surveillance pipelines (WHO Global Hepatitis Programme, national seroprevalence surveys) from the IARC GLOBOCAN cancer registry pipeline. Treated as an independent line of evidence on the risk-factor side even though the downstream liver cancer mortality numbers are partially dependent via cause-of-death attribution.\n"
    },
    {
      "url": "https://www.cancer.org/cancer/types/liver-cancer/about/what-is-key-statistics.html",
      "title": "Key Statistics About Liver Cancer",
      "publisher": "American Cancer Society",
      "source_type": "reputable_reference",
      "statistic": "~42,340 new US liver cancer cases and ~30,980 deaths projected for 2026 (27,790 new cases in men, 14,550 in women; 19,650 deaths in men, 11,330 in women); US liver cancer incidence has tripled over the past four decades",
      "excerpt": "\"About 42,340 new cases (27,790 in men and 14,550 in women) will be diagnosed [...] About 30,980 people (19,650 men and 11,330 women) will die of these cancers [...] Liver cancer incidence rates have tripled in the US over the past 4 decades.\"\n",
      "source_date": "2026-01-13",
      "source_accessed": "2026-04-11",
      "archive_url": "https://web.archive.org/web/20260426203236/https://www.cancer.org/cancer/types/liver-cancer/about/what-is-key-statistics.html",
      "calculation_notes": "ACS figures match SEER to within ~2% and are used as the annual US aggregate anchor. The more interesting number here is the three-fold increase in US liver cancer incidence over the past four decades — most of which is attributable to (a) the HCV infection cohort born 1945-1965, (b) rising rates of NAFLD/MASLD driven by obesity and metabolic syndrome, and (c) the ageing of the population. Used as the basis for the third body paragraph on NAFLD/MASLD as an emerging risk factor.\n",
      "independence_note": "ACS and SEER share the same underlying vital-registration and cancer-registry upstream (NCHS mortality data, NAACCR incidence data). Treat as one combined US line of evidence.\n"
    }
  ],
  "comparison_anchors": [
    {
      "label": "Death from cancer (lifetime, global adult, all sites)",
      "lifetime_us_adult": 0.14
    },
    {
      "label": "Death from lung cancer (lifetime, global adult)",
      "lifetime_us_adult": 0.018
    },
    {
      "label": "Death from stroke (lifetime, global adult)",
      "lifetime_us_adult": 0.067
    },
    {
      "label": "Death from a smoking-related disease (lifelong regular smoker)",
      "lifetime_us_adult": 0.5
    },
    {
      "label": "Death from alcohol-attributable disease (lifelong heavy drinker)",
      "lifetime_us_adult": 0.15
    },
    {
      "label": "Death in a car crash (lifetime, US)",
      "lifetime_us_adult": 0.0108
    },
    {
      "label": "Death in a plane crash (lifetime, US adult, regular flyer)",
      "lifetime_us_adult": 0.000017
    }
  ],
  "regional_breakdown": [
    {
      "region": "Global average",
      "probability": 0.015,
      "notes": "~758K liver cancer deaths/yr across ~6B adults (GLOBOCAN 2022); age-weighted lifetime"
    },
    {
      "region": "East/Southeast Asia",
      "probability": 0.04,
      "notes": "Dominated by chronic hepatitis B; Eastern Asia alone accounts for roughly half of global liver cancer deaths, reflecting decades of endemic HBV transmission before the vaccination era"
    },
    {
      "region": "Sub-Saharan Africa",
      "probability": 0.025,
      "notes": "HBV plus dietary aflatoxin exposure; incidence is high but competing mortality and under-reporting make the absolute lifetime figure uncertain"
    },
    {
      "region": "US adult",
      "probability": 0.007,
      "notes": "SEER lifetime diagnosis ~1.1%, 5-year survival ~22%, implied lifetime mortality ~0.7-0.9%; rising over the past four decades"
    },
    {
      "region": "Western Europe",
      "probability": 0.008,
      "notes": "Lower than East Asia; burden increasingly driven by HCV legacy infection, alcohol, and NAFLD/MASLD rather than HBV"
    }
  ],
  "personal_factor_multipliers": [
    {
      "factor": "chronic hepatitis B (HBV) infection",
      "multiplier": 25,
      "notes": "Chronic HBV is the single largest global driver of hepatocellular carcinoma. Relative risk estimates from prospective cohorts range from roughly 15x to 30x vs uninfected; 25x is a rough mid-point. The risk is concentrated in carriers who acquired HBV perinatally or in early childhood, where chronicity rates exceed 90%."
    },
    {
      "factor": "chronic hepatitis C (HCV) infection",
      "multiplier": 17,
      "notes": "Chronic HCV is the dominant driver of liver cancer in high-income countries with lower HBV prevalence. The US 1945-1965 birth cohort carries a disproportionate HCV burden and accounts for much of the historical tripling of US liver cancer incidence. Direct-acting antivirals introduced after 2013 materially reduce but do not eliminate HCC risk."
    },
    {
      "factor": "heavy alcohol use + HCV",
      "multiplier": 35,
      "notes": "Alcohol and chronic viral hepatitis interact roughly multiplicatively for HCC risk. Heavy drinking combined with chronic HCV produces one of the highest documented liver cancer risk profiles in the epidemiological literature; this interaction drives the regular-drinking-death entry’s 4x HBV/HCV co-infection multiplier."
    },
    {
      "factor": "non-alcoholic fatty liver disease (NAFLD/MASLD)",
      "multiplier": 2,
      "notes": "NAFLD/MASLD is the emerging liver cancer driver in wealthy countries, tied to obesity, type 2 diabetes, and metabolic syndrome. Relative risk estimates are lower than for chronic viral hepatitis (roughly 2x for the general NAFLD population, rising sharply for those who progress to NASH-cirrhosis), but the exposed population is vastly larger, so the population-attributable fraction is rising."
    },
    {
      "factor": "HBV vaccinated",
      "multiplier": 0.1,
      "notes": "The hepatitis B vaccine is ~95% effective at preventing chronic infection when administered in infancy. Taiwan’s universal infant HBV vaccination programme, launched in 1984, produced a ~70% reduction in childhood HCC incidence within two decades — the clearest real-world demonstration of a cancer intervention driven by vaccination."
    },
    {
      "factor": "heavy alcohol use (lifelong)",
      "multiplier": 4,
      "notes": "Heavy drinking alone raises liver cancer risk through the alcoholic-cirrhosis pathway. Effect is smaller than chronic viral hepatitis but interacts multiplicatively with HBV, HCV, and NAFLD."
    }
  ],
  "short_label": "Liver cancer",
  "myth_framing": "underrated",
  "outcome_severity": "fatal",
  "exposure_pattern": "recurring",
  "outcome_type": "chronic_illness",
  "valence": "negative",
  "caveats": "Liver cancer is the Likelier entry with the largest region-to-region variance of any cancer on the site, and a single headline number does a worse job than usual of summarising a reader’s actual risk. The ~1 in 60 global lifetime figure is an average across a population where East Asia and Sub-Saharan Africa carry a disproportionately large share of the global burden and where North America and Western Europe sit at roughly a third of the global age-standardised rate. The single biggest determinant of individual risk is chronic hepatitis B or hepatitis C status, which is binary for any given person and moves the lifetime number by more than an order of magnitude. The US number is itself moving: ACS reports US liver cancer incidence has tripled over the past four decades, driven partly by the HCV-exposed 1945-1965 birth cohort and partly by the rising NAFLD/MASLD burden, and is expected to continue rising as the NAFLD cohort ages. On the other side, universal infant HBV vaccination — routine in most countries since the 1990s — has already begun to bend the incidence curve in post-vaccination birth cohorts in Taiwan, mainland China, and elsewhere. The global liver cancer picture over the next 30 years is an uneven mix of falling HBV-driven incidence in vaccinated Asian cohorts and rising NAFLD-driven incidence in metabolically-unwell Western cohorts. Finally, \"liver cancer\" here is dominated by hepatocellular carcinoma (HCC), which is ~80% of primary liver cancer globally; intrahepatic cholangiocarcinoma and other subtypes are lumped in with HCC in the SEER and GLOBOCAN headline figures but have different risk-factor profiles and prognoses.\n",
  "quality_score": {
    "d1": 5,
    "d2": 5,
    "d3": 4,
    "d4": 4,
    "d5": 5,
    "d6": 5,
    "d7": 5,
    "d8": 5,
    "avg": 4.75,
    "scored_by": "claude-code-8d",
    "scored_at": "2026-05-25",
    "methodology_version": "1.2"
  },
  "reviewer": "likelier-phase-5-agent",
  "last_reviewed": "2026-04-11",
  "reviewed": true,
  "generated_at": "2026-04-11",
  "image": {
    "alt": "A single pale oblong shape with an uneven boundary on a muted sand background, flat vector illustration."
  },
  "attribution": "Likelier — https://likelier.app",
  "license": "https://creativecommons.org/licenses/by-sa/4.0/",
  "support": "https://buymeacoffee.com/kgluszczyk?via=likelier&utm_content=api-fear-single",
  "canonical_url": "https://likelier.app/liver-cancer"
}